RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (the “Company” or “RegeneRx”) announced today that it received a “Notice of Allowance” in Europe for its patent application: Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides. The patent covers methods, uses and compositions containing thymosin beta 4 (Tβ4), and variations and components thereof, to improve the appearance of skin, including skin that is aged, dry, lined and wrinkled.

“We are pleased to have received the ‘Notice of Allowance’ from the European Patent Office for this important patent, which is one of the cornerstones of our intellectual property related to potential cosmeceutical products. This, and other patents we have subsequently filed, if issued, should provide a solid foundation for developing and protecting synthetic peptides that we believe will be important to the cosmetics industry and our efforts to create novel, scientifically-based cosmeceutical products to address this fast-growing market segment,” stated J.J. Finkelstein, RegeneRx’s president and chief executive officer.